Evidence map›Paper›PMID 22510384›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2012

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Paul J Martin, J Douglas Rizzo, John R Wingard, Karen Ballen, Peter T Curtin, Corey Cutler, Mark R Litzow, Yago Nieto, Bipin N Savani, Jeffrey R Schriber and 3 more

3 registry-linked trialsOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 295 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
295citing papers in PubMed, 10 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02379442 phase1 / phase2terminatednot on this mapstarted 2015, after this paper: background citation

A Pilot Study of Early Treatment of Acute Graft Versus Host Disease With Bone Marrow- Derived Mesenchymal Stem Cells and Corticosteroids: Correlation of Disease Severity and Response With Biomarkers

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2015 to 2017Enrolled1ConditionsGraft-Versus-Host DiseaseArmsMSC
NCT07576699 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

TypeinterventionalSponsorCellenkos, Inc.Ran2026 to 2029Enrolled12ConditionsSteroid Refractory Graft Versus Host DiseaseArmsCK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
NCT07708987 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase II Clinical Trial of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease

TypeinterventionalSponsorTata Memorial CentreRan2023 to 2028Enrolled34ConditionsHematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod RefractoryArmsStandardized Withaferin A (SWA)
3 · Its place in the literature

Who cites it

295 citing papers in PubMed, 10 syntheses or guidelines pooled it, 640 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

235 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 2 countries.

Paul J MartinFred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA. pmartin@fhcrc.org
J Douglas Rizzo
John R Wingard
Karen Ballen
Peter T Curtin
Corey Cutler
Mark R Litzow
Yago Nieto
Bipin N Savani
Jeffrey R Schriber
Paul J Shaughnessy
Donna A Wall
Paul A Carpenter
CancerCare Manitoba · CACHRISTUS Transplant Institute · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USMassachusetts General Hospital · USMayo Clinic · USMedical College of Wisconsin · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Diego · USUniversity of Florida · USUniversity of Washington · USVanderbilt University Medical Center · US

Funding

VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Newell · 1985 to 2026
$128.4M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
NCATS NIH HHS UL1 TR000064NCI NIH HHS CA18029NCI NIH HHS P01 CA018029
6 · The paper itself

Abstract

Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies.

Indexed as

GlucocorticoidsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsMethylprednisolonePrednisoneTransplantation ConditioningGlucocorticoidsImmunosuppressive AgentsMethylprednisolonePrednisone

Identifiers

PMID22510384
PMCPMC3404151
OpenAlexW2143258371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.